In yet another blow to drug maker Wockhardt, US Food and Drug Administration (USFDA) has banned import of products manufactured at its Ankleshwar plant for non compliance of manufacturing norms.
The company’s Ankleshwar plant manufactures bulk drugs, the USFDA said in a notice on its website. The import alert has been issued under ‘Import Alert 66-40’, which authorises the health regulator “detention without physical examination of drugs from firms which have not met drug GMPs”.
Already the company’s two plants at Chikalthana and Waluj have been banned from exporting drugs to the US by the US health regulator. In November 2013, the USFDA had imposed restrictions on import of medicines produced at the company’s Chikalthana plant at Aurangabad in Maharashtra.
Earlier in May, the USFDA had also issued an import alert on the company’s Waluj facility which makes injectables and solid dosages. Wockhardt shares ended at Rs.1,015.60 on BSE, up 0.49% from the previous close.
Like this report? Sign up for our daily newsletter to get our top reports.
Leave Your Comment
5 years ago
In another setback to Mumbai-based generic drugmaker Wockhardt Ltd, it has...
4 years ago
The US Food and Drug Administration (USFDA) has issued a warning letter to...
5 years ago
Daiichi Sankyo controlled pharma major Ranbaxy Laboratories Ltd’s shares...